Literature DB >> 10604342

Progressive osteoporosis during androgen deprivation therapy for prostate cancer.

H W Daniell, S R Dunn, D W Ferguson, G Lomas, Z Niazi, P T Stratte.   

Abstract

PURPOSE: Hypogonadism is a prominent risk factor for osteoporosis in older men. However, bone loss during androgen ablation therapy for prostate cancer has rarely been quantitated.
MATERIALS AND METHODS: Femoral neck bone mineral density was determined in 26 men before orchiectomy or chemical castration as initial hormone therapy for prostate cancer and at 6-month intervals thereafter for 6 to 42 months. Measurements were made in 16 other men at 12 to 24 months beginning 3 to 8 years after the onset of castration. Baseline and post-castration bone loss was related to several host and tumor characteristics, and compared to similar measurements in 12 control subjects.
RESULTS: Average age corrected baseline femoral neck bone mineral density was higher in controls than in treated men and remained essentially unchanged for 2 years. Following orchiectomy average bone mineral density decreased 2.4% and 7.6%, respectively, during years 1 and 2 (2-year loss 2.5% to 17.0%), with similar losses documented in men undergoing chemical castration. Average bone mineral density decreased 1.4% to 2.6% per year 3 to 8 years after uninterrupted androgen deprivation. Age corrected baseline bone mineral density was greater in men who were obese, younger than 75 years or participated in regular exercise but the influence of each characteristic could not be isolated. Post-castration bone loss was greater in men who were obese, younger than 75 years without regular exercise.
CONCLUSIONS: Chemical or surgical castration in men with prostate cancer is usually followed by greatly accelerated bone loss which may be superimposed on a bone mass already depleted before hormonal therapy. Baseline bone mass and subsequent bone loss may be influenced by host obesity, age and exercise habits.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10604342

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  81 in total

1.  Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors.

Authors:  Claudia Bighin; Gianluigi Lunardi; Lucia Del Mastro; Paola Marroni; Paola Taveggia; Alessia Levaggi; Sara Giraudi; Paolo Pronzato
Journal:  Oncologist       Date:  2010-12-08

2.  Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.

Authors:  Kouta Ito; Elena B Elkin; Monica Girotra; Michael J Morris
Journal:  Ann Intern Med       Date:  2010-05-18       Impact factor: 25.391

Review 3.  Drug-induced osteoporosis: beyond glucocorticoids.

Authors:  Karine Briot; Christian Roux
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

4.  Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study.

Authors:  May Darwish-Yassine; Manijeh Berenji; Diane Wing; Glenn Copeland; Raymond Y Demers; Carol Garlinghouse; Angela Fagerlin; Gail E Newth; Laurel Northouse; Margaret Holmes-Rovner; David Rovner; Jerry Sims; John T Wei
Journal:  J Cancer Surviv       Date:  2013-11-10       Impact factor: 4.442

5.  Managing bone loss and bone metastases in prostate cancer patients: a focus on bisphosphonate therapy.

Authors:  Ron S Israeli
Journal:  Rev Urol       Date:  2008

Review 6.  Bone health and prostate cancer.

Authors:  P J Saylor; M R Smith
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-11-10       Impact factor: 5.554

Review 7.  Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.

Authors:  Alicia K Morgans; Matthew R Smith; A James O'Malley; Nancy L Keating
Journal:  Cancer       Date:  2012-10-12       Impact factor: 6.860

Review 9.  A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma.

Authors:  Ary Serpa Neto; Marcos Tobias-Machado; Marcos A P Esteves; Marília D Senra; Marcelo L Wroclawski; Fernando L A Fonseca; Rodolfo B dos Reis; Antônio C L Pompeo; Auro Del Giglio
Journal:  BMC Urol       Date:  2010-05-19       Impact factor: 2.264

Review 10.  Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.

Authors:  Philip J Saylor; Nancy L Keating; Matthew R Smith
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.